Deferoxamine — Membership Pricing

Other medications in Blood & Hematology

• Fondaparinux
• Dalteparin
• Deferasirox

What Deferoxamine is approved for (FDA label)

Deferoxamine Mesylate for Injection is an iron-chelating agent indicated: • As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) • For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine Mesylate for Injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). 1.1 Acute Iron Intoxication Deferoxamine Mesylate for Injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. 1.2 Chronic Iron Overload Deferoxamine Mesylate for Injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia. 1.3 Limitations of Use Deferoxamine Mesylate for Injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder).

Source: Read the full FDA label on DailyMed. Label effective date: June 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Deferoxamine (FDA label)

For injection: 500 mg of deferoxamine mesylate (corresponding to 426.82 mg of deferoxamine as free base) is a white to off-white lyophilized powder in a single-dose vial for reconstitution. For injection: 2 grams of deferoxamine mesylate (corresponding to 1.707 g of deferoxamine as free base) is a white to off-white lyophilized powder in a single-dose vial for reconstitution. For injection: 500 mg and 2 g of deferoxamine mesylate is a white to off-white lyophilized powder in single-dose vial for reconstitution ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d91e16df-8daa-4cd2-86a2-273eaa2446e0. SPL document ID: 723278d4-d701-4b94-a615-ac07a1305e2d. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Deferoxamine (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] • Auditory and Ocular Toxicity [see Warnings and Precautions ( 5.2 )] • Renal Toxicity [see Warnings and Precautions ( 5.3 )] • Respiratory Toxicity [see Warnings and Precautions ( 5.4 )] • Growth Suppression [see Warnings and Precautions ( 5.5 )] • Serious Infections [see Warnings and Precautions ( 5.6 )] • Cardiac Dysfunction with Concomitant Use of Vitamin C [see Warnings and Precautions ( 5.7 )] • Risks of Deferoxamine Mesylate for Injection Treatment in Patients with Aluminum Overload [see Warnings and Precautions ( 5.8 )] • Effects on Ability to Drive and Use Machines [see Warnings and Precautions ( 5.9 )] Most common adverse reactions are injection reactions (local and systemic), hypersensitivity reactions, infections with Yersinia and Mucormycosis, cardiovascular, gastrointestinal, hematologic, hepatic, musculoskeletal, urogenital, nervous, respiratory, ocular and hearing. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi, USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience The following adverse reactions associated with the use of deferoxamine mesylate for injection were identified in clinical studies or postmarketing reports.

Source: FDA prescribing information (DailyMed). Set ID: d91e16df-8daa-4cd2-86a2-273eaa2446e0. SPL document ID: 723278d4-d701-4b94-a615-ac07a1305e2d. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Deferoxamine (FDA label)

Deferoxamine Mesylate for Injection is contraindicated in patients with: • A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see Description ( 11 )] . Reactions have included anaphylaxis [see Warnings and Precautions ( 5.1 )] . • Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see Warnings and Precautions ( 5.3 )] . • Known hypersensitivity to the active substance. ( 4 ) • Patients with severe renal disease or anuria. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: d91e16df-8daa-4cd2-86a2-273eaa2446e0. SPL document ID: 723278d4-d701-4b94-a615-ac07a1305e2d. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Deferoxamine (FDA label)

• Hypersensitivity Reactions: More common with rapid intravenous infusion. Administer intramuscularly or by slow subcutaneous or intravenous infusion. ( 5.1 ) Auditory and Ocular Toxicity: Have been reported when administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. ( 5.2 ) • Renal Toxicity: Cases of acute renal failure, renal tubular disorders and increase in serum creatinine have occurred. Monitor patients for changes in renal function. ( 5.3 ) • Respiratory Toxicity: Acute respiratory distress syndrome has occurred. Risk increased with high intravenous doses. Recommended daily dose should not be exceeded. ( 5.4 ) • Growth Suppression: Has occurred in pediatric patients treated with high doses and concomitant low ferritin levels. Dose reduction may partially resume growth velocity to pre-treatment rates. ( 5.5 ) • Serious Infections: Cases of mucormycosis and Yersinia infections, some fatal, have occurred.

Source: FDA prescribing information (DailyMed). Set ID: d91e16df-8daa-4cd2-86a2-273eaa2446e0. SPL document ID: 723278d4-d701-4b94-a615-ac07a1305e2d. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Deferoxamine (FDA label)

• Concurrent treatment with prochlorperazine may lead to temporary impairment of consciousness. ( 7.1 ) • Imaging results may be distorted due to rapid urinary excretion of Deferoxamine Mesylate for Injection bound gallium-67. Discontinue Deferoxamine Mesylate for Injection 48 hours prior to scintigraphy. ( 7.2 ) 7.1 Prochlorperazine Concurrent treatment with Deferoxamine Mesylate for Injection and prochlorperazine, a phenothiazine derivative, may lead to temporary impairment of consciousness. 7.2 Gallium-67 Imaging results may be distorted because of the rapid urinary excretion of Deferoxamine Mesylate for Injection-bound gallium-67. Discontinue Deferoxamine Mesylate for Injection 48 hours prior to scintigraphy.

Source: FDA prescribing information (DailyMed). Set ID: d91e16df-8daa-4cd2-86a2-273eaa2446e0. SPL document ID: 723278d4-d701-4b94-a615-ac07a1305e2d. Label effective date: June 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.